Recent News & Research

Use of liquid biopsy in monitoring therapeutic resistance in EGFR oncogene addicted NSCLC ResearchTreatments

Use of liquid biopsy in monitoring therapeutic resistance in EGFR oncogene addicted NSCLC

*November 2020* Liquid biopsy has emerged as a minimally invasive alternative to tumor tissue analysis for the management of lung cancer patients, especially for epidermal growth factor receptor (EGFR) oncogene addicted tumor. In these patients, despite the clear benefits of tyrosine kinase inhibitors therapy, the development of acquired resistance and…
laurabbook@gmail.com
January 6, 2021
Targeted Oncology
MET Target Excites Treatment Paradigm for Patients With Lung Cancer ResearchTreatments

MET Target Excites Treatment Paradigm for Patients With Lung Cancer

*November 2020* MET mutations can be a resistance mechanism to TKI treatment (Tarceva, Tagrisso, etc.) Roman Perez-Soler, MD, professor in the Department of Medicine (Oncology) and Department of Molecular Pharmacology, and chief of the Department of Medicine Division of Oncology, Albert Einstein College of Medicine, discusses how MET mutations have evolved and…
laurabbook@gmail.com
January 6, 2021
Onc Live
Growth of Targeted Therapy Requires More Nuanced Treatment Considerations in NSCLC ResearchTreatments

Growth of Targeted Therapy Requires More Nuanced Treatment Considerations in NSCLC

*November 2020* The role of targeted therapy is rapidly expanding in the treatment paradigm of patients with non–small cell lung cancer (NSCLC), said D. Ross Camidge, MD, PhD, who added that among multiple therapeutic options for common aberrations, such as ALK, ROS1, BRAF, and MET, treatment selection should be based on more than…
laurabbook@gmail.com
January 6, 2021
How Do I Handle This Cancer Part 7 Coping With Cancer

How Do I Handle This Cancer Part 7

*December 2020* by Tess Taft, msw, licsw ©all rights reserved This is the seventh part of a series on how people cope with cancer. The first installment discussed GRIEF, DEPRESSION, and ANXIETY. The second installment included thoughts on ANGER.The third installment spoke to people who manage their feelings by WITHDRAWAL and RESIGNATION. The fourth part addressed how people handle…
laurabbook@gmail.com
January 6, 2021
Oncogene-specific advocacy groups bring a patient-centric perspective to studies of lung cancer Advocacy

Oncogene-specific advocacy groups bring a patient-centric perspective to studies of lung cancer

*November 2020* Communities sharing particular types of the disease are helping steer research towards better therapies. Patient advocates often want immediate results but this can be at odds with the slow pace of scientific investigation. Yet clinicians and scientists who have collaborated with advocacy groups say they are an invaluable…
laurabbook@gmail.com
January 6, 2021
MedicalXpress
New study shows SHP2 inhibition overcomes multiple therapeutic-resistance mechanisms in lung cancer ResearchTreatments

New study shows SHP2 inhibition overcomes multiple therapeutic-resistance mechanisms in lung cancer

*September 2020* New preclinical research from The University of Texas MD Anderson Cancer Center and BridgeBio Pharma, Inc. affiliate Navire Pharma, Inc., finds that the novel SHP2 inhibitor IACS-13909 is able to overcome multiple therapeutic-resistance mechanisms in non-small cell lung cancer (NSCLC), suggesting a possible new approach to treating cancers…
laurabbook@gmail.com
January 6, 2021
Onc Live
Targeted Therapy Research Booms in Biomarker-Positive NSCLC ResearchTreatments

Targeted Therapy Research Booms in Biomarker-Positive NSCLC

*October 2020* Shirish M. Gadgeel, MD, MBBS, highlights some of the recent targeted therapy advances in NSCLC and how ongoing research is taking the paradigm to the next level. The molecular landscape of non–small cell lung cancer (NSCLC), especially with EGFR mutations and acquired resistance, continues to get more complex as preliminary…
laurabbook@gmail.com
January 6, 2021
Onc Live
Identifying, Treating Resistance to TKIs Are Next Step in EGFR+ NSCLC ResearchTreatments

Identifying, Treating Resistance to TKIs Are Next Step in EGFR+ NSCLC

*October 2020* Identifying how to best treat patients who develop resistance to EGFR-targeted therapy, especially frontline osimertinib (Tagrisso), is part of the next chapter of research in this molecularly driven non–small cell lung cancer (NSCLC) arena, explained Christina Baik, MD, MPH.​ “It’s important to understand that there is now another option…
laurabbook@gmail.com
January 6, 2021